Tarix enrolls first patient in TXA127 study
Tarix Pharmaceuticals has enrolled the first patient in a phase I clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
The study will evaluate the safety of TXA127 following double cord blood stem cell transplant (DCBT) in adult patients with hematological cancers. The study will also compare the time to engraftment for patients receiving TXA127 to that of historical controls in order to assess the efficacy of TXA127 in speeding up the engraftment process.
Tarix expects to conduct multiple open-label phase I clinical studies of TXA127 designed to evaluate the safety and efficacy of TXA127 in the acceleration of engraftment following double cord blood stem cell transplant, involving adult and pediatric patients. The first phase I study described above is expected to enroll approximately 10 adult patients with acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma (HL), or non-Hodgkin's lymphoma (NHL) at The MD Anderson Cancer Center in Texas.